  
- 积分
- 4277
- 威望
- 4277
- 包包
- 7646
|
Nature Cell Biology 12, 468 - 476 (2010) ' L T; B" T V8 \. f( f
Published online: 25 April 2010 | doi:10.1038/ncb2048. v J$ i6 F* @$ a
2 @2 B( E3 |, v* h: d; k# p) b" D4 O% x
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. N# m+ u& X* Z7 C& R
Louis Vermeulen1,5, Felipe De Sousa E Melo1,5, Maartje van der Heijden1, Kate Cameron1, Joan H. de Jong1, Tijana Borovski1, Jurriaan B. Tuynman1, Matilde Todaro2, Christian Merz3, Hans Rodermond1, Martin R. Sprick1, Kristel Kemper1, Dick J. Richel1, Giorgio Stassi2,4 & Jan Paul Medema1
5 F. x8 C- f5 N2 B1 L
e# J, i, [0 S8 k1 d P' e2 R8 `# `& D/ B/ h/ P
) G% P( {. e4 u' g8 i--------------------------------------------------------------------------------
) D: g7 T7 S# y- O+ h, m3 I. P5 i# [
AbstractDespite the presence of mutations in APC or β-catenin, which are believed to activate the Wnt signalling cascade constitutively, most colorectal cancers show cellular heterogeneity when β-catenin localization is analysed, indicating a more complex regulation of Wnt signalling. We explored this heterogeneity with a Wnt reporter construct and observed that high Wnt activity functionally designates the colon cancer stem cell (CSC) population. In adenocarcinomas, high activity of the Wnt pathway is observed preferentially in tumour cells located close to stromal myofibroblasts, indicating that Wnt activity and cancer stemness may be regulated by extrinsic cues. In agreement with this notion, myofibroblast-secreted factors, specifically hepatocyte growth factor, activate β-catenin-dependent transcription and subsequently CSC clonogenicity. More significantly, myofibroblast-secreted factors also restore the CSC phenotype in more differentiated tumour cells both in vitro and in vivo. We therefore propose that stemness of colon cancer cells is in part orchestrated by the microenvironment and is a much more dynamic quality than previously expected that can be defined by high Wnt activity.
* q& n. c, a7 U' r1 Q2 f* R, p; u1 m7 a4 ^* [
Top of page
/ O7 y; t, ^$ X% X--------------------------------------------------------------------------------+ Z2 w3 X( g' E7 x0 O6 v
6 v* X1 h) U# @& ^9 Y1 z9 N
Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
9 B8 v V9 Y. s8 BDepartment of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 90127 Palermo, Italy.9 \5 s& p# k6 W- [
APOGENIX GmbH, 69120 Heidelberg, Germany./ {2 ?( r% w- w z2 m; p) V2 Y
Present address: Cellular and Molecular Oncology, IRCCS Fondazione Salvatore Maugeri, 27100 Pavia, Italy.
: p b! n4 ^8 p) j4 hThese authors contributed equally to this work.* `$ ^5 ?6 _! b2 V3 K- r9 c: J
Correspondence to: Jan Paul Medema1 e-mail: J.P.Medema@amc.uva.nl |
-
总评分: 威望 + 5
包包 + 10
查看全部评分
|